Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study

Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study

<b>Background/Objectives:</b> The burden of chronic kidney disease (CKD) is increasing, as is the prevalence of type 2 diabetes mellitus (T2DM). Post-hoc analyses of clinical trials support that sodium–glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptors ago...

Full description

Bibliographic Details
Main Authors: Antonio Rodríguez-Miguel, Beatriz Fernández-Fernández, Alberto Ortiz, Miguel Gil, Sara Rodríguez-Martín, Gema Ruiz-Hurtado, Encarnación Fernández-Antón, Luis M. Ruilope, Francisco J. de Abajo
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Pharmaceuticals
Subjects:
chronic kidney disease
GLP-1 receptor agonists
glucose-lowering drugs
primary prevention
SGLT-2 inhibitors
type 2 diabetes
Online Access:https://www.mdpi.com/1424-8247/17/10/1299

Internet

https://www.mdpi.com/1424-8247/17/10/1299

Similar Items